

CITATION REPORT

List of articles citing

Glucocorticoids in . Ten Questions and Some Issues

DOI: 10.3390/jcm9092709

Journal of Clinical Medicine, 2020, 9, .

Source: <https://exaly.com/paper-pdf/76218187/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Extracellular Vesicles in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Functions and Applications. <i>Frontiers in Immunology</i> , 2020 , 11, 575712	8.4	5
31	Safety considerations when using drugs in pregnant patients with systemic lupus erythematosus. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 523-536	4.1	0
30	Clinical Description of Patients with Systemic Lupus Erythematosus Evaluated in a Specialized Center for Rheumatic Diseases in Guatemala City.		
29	Descripci3n cl3nica de pacientes con Lupus Eritematoso Sist3mico evaluados en un Centro Especializado en Enfermedades Reum3ticas de la Ciudad de Guatemala (AGAR).		
28	Snail mucus suppresses anti dsDNA antibodies in lupus mice. <i>IOP Conference Series: Earth and Environmental Science</i> , 2021 , 824, 012058	0.3	
27	Long-term (16-26 years) follow-up outcome of steroid therapy in refractory autoimmune sensorineural hearing loss. <i>Journal of Autoimmunity</i> , 2021 , 121, 102664	15.5	1
26	The prevalence and mortality of cryptococcal meningitis in patients with autoimmune diseases: a systematic review and meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 2515-2523	5.3	0
25	Systemic Lupus Erythematosus Pregnancy.		0
24	What are the benefits and harms of belimumab for patients with systemic lupus erythematosus?: A Cochrane Review summary with commentary. <i>International Journal of Rheumatic Diseases</i> , 2021 , 24, 1331-1333	2.3	1
23	The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	17
22	Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?. <i>Journal of Clinical Rheumatology</i> , 2021 ,	1.1	1
21	Gut Microbiota Dysbiosis in Systemic Lupus Erythematosus: Novel Insights into Mechanisms and Promising Therapeutic Strategies.. <i>Frontiers in Immunology</i> , 2021 , 12, 799788	8.4	7
20	In Vitro Characterization of Sphingosine 1-Phosphate Receptor 1 (S1P) Expression and Mediated Migration of Primary Human T and B Cells in the Context of Cenerimod, a Novel, Selective S1P Receptor Modulator.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	0
19	Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus.. <i>Inflammation Research</i> , 2022 , 1	7.2	1
18	Prednisone and long-term damage in systemic lupus erythematosus: Which is the threshold dose? A pilot study.. <i>Lupus</i> , 2022 , 9612033221093485	2.6	0
17	Successful treatment of children with juvenile systemic sclerosis using mycophenolate mofetil after methylprednisolone pulse therapy: A 3-year follow-up. <i>International Journal of Rheumatic Diseases</i> , 2021 ,	2.3	
16	Clinical Efficacy of Gandakang Tablets plus Methylprednisolone in Patients with Systemic Lupus Erythematosus.. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022 , 2022, 4797454	2.3	

15	Efficacy of plasma exchange on top of standard immunosuppressive therapy in adult autoimmune inflammatory rheumatic diseases-associated macrophage activation syndrome, a single center real-world analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 55, 152043	5.3	○
14	Analysis of Peripheral Blood Basophils in Pediatric Systemic Lupus Erythematosus. <i>Diagnostics</i> , 2022 , 12, 1701	3.8	○
13	Systemic lupus erythematosus: history and modernity. 2022 , 60, 397-412		2
12	Jieduquyuziyin prescription promotes the efficacy of prednisone via upregulating Nrf2 in MRL/lpr kidneys. 2022 , 298, 115643		○
11	Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis. 2022 , 57, 152099		○
10	Safety and efficacy of low-dose glucocorticoid regimen in the induction phase treatment of class 4, 5 lupus nephritis: a retrospective study. 2022 , 22, 148		○
9	Comparative effects of human-equivalent low, moderate, and high dose oral prednisone intake on autoimmunity and glucocorticoid-related toxicity in a murine model of environmental-triggered lupus. 13,		○
8	An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. 2022 ,		○
7	Adherence to antimalarials and glucocorticoids treatment and its association with self-reported disease activity in systemic lupus erythematosus patients. 096120332211383		○
6	The effects of glucocorticoid treatment on cardiovascular system in patients with systemic lupus erythematosus. 2022 , 37, 495-503		○
5	Glucocorticoid Effects on Proteoglycans and Glycosaminoglycans. 2022 , 23, 15678		1
4	Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety. 2023 , 59, 56		○
3	Influence of perception of glucocorticoids on compliance of treatment in patients with rheumatoid arthritis and systemic lupus erythematosus. 2023 , 45, 159-164		○
2	Lupus RGMX: Social and Clinical Characteristics and their Contribution to Quality of Life in a Mexican Cohort with SLE.		○
1	Therapeutic potential of the current options in treating systemic lupus erythematosus: Challenges and prospective. 2023 , 333-348		○